GSK underlines commitment to China with £2million public-partnership to train doctors
22 October 2015
3 year partnership with National Health and Family Planning Commission of China
Seven-thousand Chinese doctors are to receive independent training in the diagnosis and treatment of Hepatitis B it was announced today during President Xi’s State visit to the UK.
GSK is funding the £2million programme and Chief Executive Officer Sir Andrew Witty announced the new commitment as he attended a business summit held in London today [21 October] and attended by President Xi.
The announcement reaffirms GSK’s long-term commitment to serving China and the healthcare needs of patients in the country. Hepatitis B has been identified as a healthcare priority in China, with approximately 20 million sufferers across the country remaining untreated.
Run over 3 years and delivered by Development Center for Medical Science and Technology, National Health and Family Planning Commission of China the training programme will equip doctors with the skills to diagnose, treat and provide ongoing management to patients.
Today’s announcement follows a similar commitment made last month to provide independent training to Chinese doctors in respiratory condition, chronic obstructive pulmonary disease (COPD).
GSK Chief Executive Officer Sir Andrew Witty said:
“Enabling medical education in China is an important part of our commitment to supporting grass roots professionals to improve their diagnosis and treatment of patients. This is one example of how GSK is seeking to support the reforms of the Chinese government and in doing so help improve the health of China’s people.”
GSK has committed £6million for public health initiatives in China over the next 5 years with around £4million being spent on independent GP training. In a further sign of GSK’s commitment to the China, GSK’s HIV business announced in July that it is signing a strategic manufacturing with Desano Pharmaceuticals to enable production in China of dolutegravir, the active ingredient in our latest HIV medicine. The agreement will allow a competitive supply of the finished product for China and a number of developing countries, subject to national approvals.